Overactive Bladder (OAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Overactive Bladder (OAB) Market Outlook

Thelansis’s “Overactive Bladder (OAB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Overactive Bladder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Overactive Bladder (OAB) Overview

The International Continence Society defines overactive bladder (OAB) as a syndrome characterized by urinary urgency, often accompanied by increased frequency and nighttime urination (nocturia), with or without the presence of urgency urinary incontinence (UI), and in the absence of urinary tract infection (UTI) or evident pathology. OAB can manifest with or without incontinence, termed OAB (wet) and OAB (dry). The exact cause of overactive bladder is not thoroughly understood, but it is believed to result from a combination of factors. The lower urinary tract serves two primary functions: storing and eliminating urine. The interplay between these functions is controlled by a network of neurotransmitters operating through both autonomic and somatic pathways. When involuntary contractions of the detrusor muscle, known as detrusor overactivity, occur spontaneously or in response to stimuli, as observed during urodynamic assessments, it leads to the development of an overactive bladder, with or without accompanying incontinence. Around 90% of cases involving detrusor overactivity causing symptoms of urgency and frequency, with or without incontinence, are idiopathic in nature, lacking an identifiable cause. Nonetheless, neurological issues, anatomical irregularities within the lower urinary tract, and other disorders can contribute to or worsen detrusor overactivity. Relevant diagnostic measures comprise urinalysis and, if irritative bladder symptoms and significant microhematuria are present on urinalysis, potentially urine cytology. Conditions like UTIs and chronic irritative bladder ailments can mimic the symptoms of OAB. The assessment of postvoid residual volume (typically <150 mL) can assist in ruling out overflow incontinence. The management of overactive bladder encompasses addressing any underlying and reversible medical conditions that contribute to the syndrome. This might involve employing antibiotics for bladder infections, addressing stress UI through surgical, weight-related, or medical interventions, and optimizing glucose regulation in diabetes. The ultimate aim is to progress toward treatments that specifically target the symptoms related to the bladder.

• The prevalence of overall OAB is comparable between women and men (16.9% vs. 16.0%). Nevertheless, while the occurrence of OAB with or without urge-UI is similar in women (9.3% and 7.6%, respectively), men tend to experience OAB without urge-UI more frequently than OAB with urge-UI (13.4% and 2.6%, respectively). 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: